Supreme Court stays 5th Circuit mifepristone in-person dispensing rule to 11 May 2026
→Telehealth prescribers and mail-order pharmacy compliance teams handling mifepristone retain telemedicine and mail dispensing only until the administrative stay expires on 11 May 2026
- → Telehealth clinic operators and mail-order pharmacy compliance teams must scope mifepristone prescribing and dispensing without in-person visit to within the 11 May 2026 stay window — post-expiry operations become unlawful if the 5th Circuit rule reattaches.
- → Mifepristone manufacturers' legal teams (Danco Laboratories; GenBioPro) must prosecute emergency relief on the Supreme Court's briefing schedule — Louisiana's response deadline (Thursday) and stay expiry (11 May 2026) control whether current dispensing rules remain operative.
Unlock the decision layer.
Get the implications, affected teams, what to watch, and Clarify with AI — so the change becomes easier to act on.